Genmab announces new results fom Phase 1b/2 EPCORE NHL-2 trial
Genmab (GMAB) announced new results from the Phase 1b/2 EPCORE NHL-2 trial Arm 10, evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab, ifosfamide, carboplatin, and etoposide, R-ICE, in adult patients with relapsed/refractory diffuse large B-cell lymphoma, R/R DLBCL, who are eligible for autologous stem cell transplantation, ASCT. Results demonstrated an overall response rate, ORR, of 87 percent, a complete response rate of 65 percent and a partial response of 23 percent. The majority of patients proceeded to ASCT. At six months, an estimated 81 percent of responses were ongoing, 74 percent of patients were progression free, and 100 percent of patients were alive. These results were shared today during an oral presentation at the 30th European Hematology Association 2025 Congress. The safety profile of this combination therapy showed cytokine release syndrome being low grade and no discontinuations due to treatment-emergent adverse events. The most common TEAEs were neutropenia, anemia, and thrombocytopenia. CRS occurred in 52 percent; all were low grade and resolved. One patient had immune effector cell-associated neurotoxicity syndrome, which resolved. No clinical tumor lysis syndrome was observed. Infections occurred in 18 patients; five had serious infections. There were no Grade 5 TEAEs.
Confident Investing Starts Here:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a day ago
- Business Wire
KIOXIA Highlights Flash Storage Solutions for What's Next in Cloud, AI, and Beyond at HPE Discover Las Vegas 2025
SAN JOSE, Calif.--(BUSINESS WIRE)--Next week at HPE ® Discover Las Vegas 2025, KIOXIA America, Inc., the inventor of NAND flash memory, will showcase how its industry-leading flash storage solutions are helping modernize IT infrastructures across cloud, AI, and hybrid environments—from the edge to the data center, and even into space. "KIOXIA is proud to highlight how our innovations are accelerating customer workloads, increasing storage efficiency, and supporting HPE's vision for AI-ready infrastructure—on Earth and beyond.' A recognized leader in flash storage and SSD technologies, KIOXIA continues to drive the industry forward with advancements making use of PCIe ® 5.0 technology, Enterprise and Datacenter Standard Form Factor (EDSFF), and 24G SAS (SAS-4). These innovations enable higher performance, increased density, and improved energy efficiency—helping customers lower total cost of ownership while advancing infrastructure optimization. As a longtime HPE collaborator, KIOXIA supports HPE's mission to accelerate data-first modernization. KIOXIA's best-in-class SSDs power a wide range of HPE solutions including enterprise servers, storage, and modern data centers—delivering consistent performance from the edge to the cloud. At this year's event, KIOXIA will also highlight its contributions to the HPE Spaceborne Computer-2 project, which leverages KIOXIA SSDs to enable cutting-edge research in a test environment aboard the International Space Station (ISS). 'Each year, at HPE Discover Las Vegas, HPE underscores how collaboration can drive digital transformation,' said Neville Ichhaporia, senior vice president and general manager of the KIOXIA SSD Business Unit. 'At this year's event, KIOXIA is proud to highlight how our innovations are accelerating customer workloads, increasing storage efficiency, and supporting HPE's vision for AI-ready infrastructure—on Earth and beyond.' KIOXIA will demonstrate its latest technologies in booth #3010 at the Venetian ® Conference and Expo Center in Las Vegas from June 23–26. Live Booth Demonstrations Featuring HPE ProLiant: Empowering Data Centers with Low Power and Fast Storage: Featuring the new KIOXIA CD9P Data Center Series Enterprise NVMe™ SSDs Accelerating Enterprise Performance with KIOXIA High Speed SSDS: Featuring KIOXIA CM9 Series Enterprise E3.S NVMe SSDs High Capacity QLC Storage for the AI Age: Featuring 122.88 terabyte KIOXIA LC9 Series Enterprise NVMe SSDs Unlocking Database Storage Potential: Featuring KIOXIA RM7 Series Enterprise Value SAS SSDs Other On-Site Demos: HPE Spaceborne Computer-2: Features 130 terabytes of KIOXIA SSDs, supporting high performance and edge computing aboard the ISS Beyond the ISS: Showcasing the next stage of space exploration for KIOXIA SSDs Life After SATA: Demonstrating the value of SAS as a cost-effective replacement for legacy SATA SSD storage KIOXIA SSD Product Lineup: Including PCIe 5.0 and Enterprise and Datacenter Standard Form Factor (EDSFF) drives New Product Highlights: KIOXIA will spotlight recently launched SSDs engineered for HPE platforms and enterprise performance: KIOXIA CD9P Series Data Center NVMe SSDs: Newly announced PCIe 5.0 NVMe 2.0 EDSFF E3.S form factor SSDs KIOXIA CM9 Series Enterprise NVMe SSDs: Next-generation NVMe SSDs built with BiCS FLASH™ Generation 8 TLC 3D flash memory KIOXIA LC9 Series Enterprise NVMe SSDs: High-capacity QLC SSDs KIOXIA will participate in several speaking sessions and panel discussions that focus on its new products and its longstanding collaboration with HPE, including: Breakout Session:"HPE and KIOXIA: Proven Data Storage from the Data Center to Outer Space" June 24 at 2:30pm (Veronese 2403) and June 25 at 3:00pm (Titian 2301B) Dr. Mark Fernandez, Principal Investigator for Spaceborne Computer-2 at HPE, explores the HPE and KIOXIA collaboration on both Earth and in space—from the Spaceborne Computer-2 project aboard the ISS to next-stage space missions. The session also discusses the critical role SSDs play in enabling next-gen workloads and sustainable storage. Expo Hall AI Theater Session:"KIOXIA and HPE: Innovation from the Data Center to Space" June 25 at 11:00am Dr. Fernandez explains how HPE and KIOXIA are working together to bring compute to space through the Spaceborne Computer project enabling advanced research on the International Space Station. This session also introduces KIOXIA's new SSD, and describes the collaboration with HPE to usher in the next phase of digital transformation in data centers. KIOXIA is also sponsoring the HPE Discover 2025 Welcome Reception and Celebration Event at Sphere, headlined by Kenny Chesney. For more information, please visit and follow the company on X, formerly known as Twitter and LinkedIn ®. About KIOXIA America, Inc. KIOXIA America, Inc. is the U.S.-based subsidiary of KIOXIA Corporation, a leading worldwide supplier of flash memory and solid-state drives (SSDs). From the invention of flash memory to today's breakthrough BiCS FLASH™ 3D technology, KIOXIA continues to pioneer innovative memory, SSD and software solutions that enrich people's lives and expand society's horizons. The company's innovative 3D flash memory technology, BiCS FLASH, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, automotive systems, data centers and generative AI systems. For more information, please visit © 2025 KIOXIA America, Inc. All rights reserved. Information in this press release, including product pricing and specifications, content of services, and contact information is current and believed to be accurate on the date of the announcement, but is subject to change without prior notice. Technical and application information contained here is subject to the most recent applicable KIOXIA product specifications. Notes: HPE and ProLiant are registered trademarks of Hewlett Packard Enterprise Company and/or its affiliates. The Venetian Resort Hotel Casino is a trademark of LAS VEGAS SANDS CORP. The NVMe word mark is a registered or unregistered trademark or service mark of NVM Express, Inc. in the United States and other countries. PCI Express and PCIe are registered trademarks of PCI-SIG. LinkedIn is a trademark of LinkedIn Corporation and its affiliates in the United States and/or other countries. Definition of capacity: KIOXIA Corporation defines a megabyte (MB) as 1,000,000 bytes, a gigabyte (GB) as 1,000,000,000 bytes and a terabyte (TB) as 1,000,000,000,000 bytes. A computer operating system, however, reports storage capacity using powers of 2 for the definition of 1GB = 2^30 bytes = 1,073,741,824 bytes and 1TB = 2^40 bytes = 1,099,511,627,776 bytes and therefore shows less storage capacity. Available storage capacity (including examples of various media files) will vary based on file size, formatting, settings, software and operating system, and/or pre-installed software applications, or media content. Actual formatted capacity may vary. Other company names, product names and service names may be trademarks of third-party companies.
Newsweek
a day ago
- Newsweek
Mexican Sewage Flooding Into California Can Be Seen From Space
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A NASA instrument aboard the International Space Station has detected contamination from Mexican sewage that spilled into the Pacific Ocean off the coast of Southern California. Why It Matters The Tijuana River flows from Mexico into California and drains into the Pacific Ocean, transporting millions of gallons of untreated sewage along with it. This long-standing issue has raised alarms over its impact on both public health and the environment. What To Know The instrument, known as the Earth Surface Mineral Dust Source Investigation (EMIT), was originally used to map minerals in desert regions but is now offering insights into water quality. In a recent study, EMIT was able to identify phycocyanin—a pigment found in cyanobacteria—within a massive wastewater plume off the mouth of the Tijuana River. A plume spreads out to sea in this image captured off San Diego by the Sentinel-2 satellite on March 24, 2023. A plume spreads out to sea in this image captured off San Diego by the Sentinel-2 satellite on March 24, 2023. SDSU/Eva Scrivner/NASA Cyanobacteria are an organism capable of causing illness in humans and animals through ingestion or inhalation, NASA said. EMIT operates by analyzing light reflected from Earth's surface, breaking it down into hundreds of visible and infrared color bands. Each material, including pollutants, has a unique spectral signature that allows scientists to identify it. Researchers matched EMIT's satellite data of the Tijuana River plume with results from ground-tested water samples. Both methods identified a spectral signature indicating the presence of phycocyanin. The findings come as Southern California beaches near the United States-Mexico border have repeatedly faced closures due to contamination. Millions of gallons of wastewater enter the Tijuana River annually, emptying into the ocean and posing a health hazard to swimmers and military personnel stationed in the area. San Diego County beaches have seen 1,000 days' worth of closures in recent years, and a report from the Department of Defense's Office of Inspector General documented 1,100 cases of illness among Navy SEALs and other service members exposed to polluted waters. What People Are Saying Christine Lee, a scientist at NASA's Jet Propulsion Laboratory and a co-author of the study, said: "From orbit you are able to look down and see that a wastewater plume is extending into places you haven't sampled. "It's like a diagnostic at the doctor's office that tells you, 'Hey, let's take a closer look at this.'" Eva Scrivner, a doctoral student at the University of Connecticut and the study's lead author, said that the findings "show a 'smoking gun' of sorts for wastewater in the Tijuana River plume." What Happens Next Lee Zeldin, the administrator of the Environmental Protection Agency, stated in May that the U.S. International Boundary and Water Commission was expediting an expansion of the South Bay International Wastewater Treatment Plant, which treats sewage and wastewater from Tijuana, by 10 million gallons per day in an effort to mitigate the crisis.
Medscape
a day ago
- Medscape
Post-Acute COVID Biomarker Patterns Vary by Symptom and Time
In patients with post-acute sequelae of SARS-CoV-2 infection (PASC), biomarker profiles varied according to symptom type and time since infection, and levels of inflammatory biomarkers (IFN gamma and CD163) and vascular activation biomarkers (VCAM-1 and ICAM-1) showed strong correlations with specific long-COVID symptoms. METHODOLOGY: PASC affects a considerable number of people after mild acute SARS-CoV-2 infection, but data on its pathophysiologic mechanisms remain limited. In this study, researchers explored symptoms associated with PASC and examined its association with a range of blood biomarkers. They included participants with prior SARS-CoV-2 infection either asymptomatic or without persistent symptoms categorized into recovered (n = 490) and PASC (n = 311) groups, using data from three French population-based cohorts collected between February 2020 and October 2021. Participants received two home visits at baseline and 6 months for biological sample collection and completed questionnaires covering medical history, infection status, vaccination status, symptoms, and mental health. Researchers assessed 14 blood biomarkers, including cytokines, chemokines, immune checkpoints, cell adhesion molecules, and markers of macrophage activation and vascular damage, which are known to be involved in the pathophysiologic mechanisms of SARS-CoV-2 infection. TAKEAWAY: Participants with PASC commonly reported persistent fatigue, breathlessness, cough, and sleep disorders, along with higher rates of depression and anxiety. Inflammatory biomarkers linked to COVID-19 severity (IFN gamma and CD163) and vascular activation markers (VCAM-1 and ICAM-1) showed significant correlations with specific PASC symptoms, particularly among participants infected within the past year; however, these associations largely disappeared over time. Viral activation markers (PD-L1 and IP-10) were positively associated with acute-phase symptoms such as anosmia/ageusia and cough, particularly in recent infections. Complete symptom resolution was more common among participants with recent infections (< 1 year ago) than among those infected a year ago, occurring in 38% vs 20% of cases ( P = .04). Overall, 74% of individuals experienced a resolution of at least one symptom. IN PRACTICE: 'Biomarker profiles appear to vary according to symptom type and the time elapsed since infection. Consequently, research efforts and treatment strategies should take these parameters into account,' the authors wrote. SOURCE: This study was led by Olivier Robineau, Sorbonne Université, Inserm, Institut Pierre-Louis d'Épidémiologie et de Santé Publique, Paris, France. It was published online on May 30, 2025, in eBioMedicine . LIMITATIONS: Individuals with more severe symptoms may have been particularly motivated to participate, introducing selection bias. Additionally, as most biomarker measurements were taken long after participants' initial infection and only a few participants had recent infections, the ability to identify associations specific to the acute phase was likely diminished. DISCLOSURES: This study received funding from the French Ministry of Health and Prevention and the French Ministry of Higher Education, Research and Innovation. Two authors disclosed receiving financial support from Gilead, ViiV, MSD, Moderna, or Pfizer or nonfinancial support from Nordic Pharma France.
